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476Quantitative and Qualitative CD4 T Cell Immune
Responses Related to Adenovirus DNAemia in
Hematopoietic Stem Cell Transplantation
Valerie Guerin-El Khourouj,1 Jean-Hugues Dalle,2 Beatrice Pedron,1 Karima Yakouben,2
Daniele Bensoussan,3 Debora Jorge Cordeiro,1 Lucas Peltier,1 Marie Ouachee-Chardin,2
Andre Baruchel,2,4 Ghislaine Sterkers1The nature of adenovirus (AdV)-specific T cells that could best predict the capacity of immunocompromised host
to fight AdV is unclear. To this aim, 47 pediatric patients were enrolled for at least 3 months either at allogeneic
bonemarrow transplantation (BMT) (23 genoidentical, 18 unrelatedofwhich 9were 10/10 and 9were 9/10HLA-
matched) or at unrelated cord blood transplantation (n5 6). Enumeration of AdV-specific CD4 T cells secreting
cytokines (flow cytometry) and proliferative responses to AdV (3HT-incorporation) were compared to AdV-
DNAemia. A total of 44/47 patients did not evidence AdV-DNAemia. Thirty-two of 44 (73%) developed CD4-
mediated interferon-gamma (IFN-g) responses to AdV (median 0.36 CD4/mL of blood) since the first month
post-HSCT(n5 11: 8 genoidentical and3unrelated)or the thirdmonth (n5 21additional patients).At 3months,
both incidence and level intensities of AdV-specific CD4 appeared similar in genoidentical and unrelated BMT
(70% and 80%; 0.36 and 0.21 CD4/mL, respectively) and not statistically different from age-matched controls
(76%; 1.35 CD4/mL), whereas cord blood transplanted patients exhibited similar incidence but higher level inten-
sities (67%; 1.49CD4/mL). Polyfunctional (IL21 IFN-g) and proliferative responses appeared later, after the third
month. Three of 4 9/10HLA-matched unrelatedHSCT that did not develop immunity to AdV presented chemo-
therapy-resistant AdV-DNAemia at 3 to 5 months post-hematopoietic stem cell transplantation (HSCT).
Two were successfully treated with AdV-specific CTL infusion. Monitoring, since month 1 post-HSCT, of IFN-
g-secreting AdV-specific CD4 appears suitable for early detection of at-risk patients especially in 9/10 HLA-
matched unrelated HSCTand preferable to monitoring of more delayed IL2- and proliferative responses.
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Adenovirus (AdV) may establish an acute as well as
persistent infection that rarely causes severe clinical
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6/j.bbmt.2010.09.010however, is a major concern in T cell deficiency status,
primarily in children. Disseminated AdV infection can
be observed in congenital immunodeficiency disorders
[1], in early age [2,3], in pediatric human immuno-
deficiency virus (HIV) infections [4], and also following
transplantation [5-7].
AdV infection in the course of hematopoietic stem
cell transplantation (HSCT) is associated with high
transplant-related morbidity and mortality. AdV infec-
tions tend to become invasive, withmolecular detection
of viremia in 2% to 6% of transplanted children [8-10].
AdV-associated disease occurred several days or weeks
following detection of adenovirus in peripheral blood
with incidence as high as 73% [8]. AdV-DNAemia
thus generally serves as a basis for early initiation of
preemptive antiviral treatment. Treatment options of
AdV infection are limited.The antiviral agents ribavirin
and cidofovir can be administered in combination
with tapering immunosuppression [11-14]. Tapering
immunosuppresion, however, is not feasible in all
patients because of the risk of graft-versus-host disease
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cient in patients who cannot develop immunity to the
virus. Combining antiviral therapy and adoptive T cell
therapy should therefore provide the best treatment
option in patients unable to reconstitute anti-AdV
immunity [15]. The unresolved issue is identification
of patients who are unable to reconstitute immunity.
Chakrabarti et al. [12] first reported an association
between post-HSCT lymphocyte recovery and AdV
infection. This observation was extended by at least 2
groups showing that severe persistent lymphopenia
[16] or low T-lymphocyte counts [17] leads to disease
progression and death despite antiviral chemotherapy,
whereas lymphocyte recovery, which is often associ-
ated with reduction of immunosuppression, can lead
to recovery. Discrepant with this observation, Myers
et al. [18], however, found no significant correlation
between lymphocyte recovery and viremia and ob-
served that absolute lymphocyte counts and even
CD4/CD8 count recovery are not necessarily reflec-
tive of the recovery of AdV-specific T cells. The recent
development of ADV-specific T cell quantification
provides promising results even though there are no
standardized assays for routine application. Using ei-
ther Elispot or flow cytometry cytokine assays, several
groups showed an association between AdV-specific
T cells secreting IFN-g and protection from lethal
infections [16-18]. However, many questions remain
unanswered with regard to the kinetics of recovery in
the context of transplant type or the threshold levels
of cellular immunity conferring protection and even
the nature of memory cells that best correlate with
the infectious risk.
OfmemoryTcells, there is a general agreement that
CD8T cells are important antiviral effector cells. More
recently, CD4 T cells gained an increasing interest for
their role in controlling and maintaining cellular im-
mune responses [19-22]. Furthermore, current reports
on the correlation between host-cellular immune
responses and infectious risk pointed to the usefulness
of CD4 analysis in addition or even in replacement of
CD8 analysis [23-27]. As an example, Pourgheysari
et al. [26] showed a clear associationbetween reconstitu-
tion of the CD41 cytomegalovirus (CMV)-specific
T cell response within the first 50 days and protection
against CMV reactivation, whereas the CD81 CMV-
specific T cell response was not predictive of protection
from a single episode of viral reactivation. The present
study, aiming at defining the patients’ ability to fight
AdV, therefore evaluated circulating AdV-specific
CD4 T cell responses that were related to AdV-
DNAemia occurrence and sensitivity to antiviral che-
motherapy in pediatric patients following HSCT.
Production of IL2- and/or proliferative-responses
in combination with IFN-g secretion have been
demonstrated with several experimental systems to
be a more accurate predictor of the protective capacityof responder T cell populations than IFN-g secretion
alone [28-33]. The previous studies on AdV infection,
however, focused on IFN-g only [17,18,34-37]. This is
the first study that investigated AdV-specific CD41
T cell responses based on the recent advances of
complex memory functions.
Finally, altered cellular immunity in young age has
been largely documented in other infections, but there
are no data on the effect of young age on the level of
intensities of AdV-specific responses. Thus, we in-
cluded in the study healthy adults and also healthy
children as reference.MATERIALS AND METHODS
Patients and Controls
Forty-seven patients who were consecutively re-
cruited at either bone marrow transplantation (BMT)
(n 5 41) or cord blood HSCT (n 5 6) from June
2006 to September 2009 and who were monitored
for AdV-specific immune recovery for at least 3
months post-HSCT were included. Part of them,
when followed for a longer period in our transplant
center, were also evaluated for immune recovery at
month 6 and/or 12 post-HSCT. All patients were
given a full-intensity myeloablative regimen. GVHD
prophylaxis consisted of cyclosporine (CSA) for pa-
tients receiving an allograft from an HLA-identical
sibling (n 5 23), whereas patients transplanted from
a matched unrelated donor (n 5 18) received a short
course of methotrexate in addition to CSA, and most
of them also received antithymocyte globulin (ATG)
before HSCT. If it occured, grade II-IV acute
GVHD (aGVHD) was treated with steroids. In all
cases, blood samples (10 mL), collected on CPDA,
were treated within the 4 hours following sampling.
This study was approved by the local Ethics Commit-
tee. Written informed consent was provided by the
parents or guardians of all children. The main charac-
teristics of patients are given in Table 1.
Thirty-four healthy children (HSCT genoidenti-
cal family donors) and 31 healthy adults (blood volun-
teer donors) were also analyzed from April 2007 to
April 2009 as reference.AdV Infections
Monitoring for AdV infection in transplanted pa-
tients consisted of weekly qualitative PCR in blood
during at least the first 3 months following HSCT.
After the third month, AdV DNAemia was also
performed in case of fever, unexplained symptoms,
laboratory test abnormalities, and GVHD. If positive,
a quantitative real-time PCR was performed [38]. An-
tiviral chemotherapy was initiated if AdV-DNA levels
Table 1. Main Characteristics of the 47 Patients Involved at
the time of HSCT
Characteristics Total (N 5 47)
Median age, years (range) 6.42 (0.41-16.25)
Male/female 24/23
Underlying disease, n (%)
Acute leukemia 35 (75 %)
Sickle-cell anemia 4 (9 %)
Juvenile myelomonocytic leukemia 4 (9 %)
Aplastic anemia 2 (4%)
Other 2 (4 %)
Source of stem cells
Bone marrow 41 (88 %)
Cord blood (4 to 6/6 HLA
matched)
6 (12 %)
HLA bone marrow donor matching,
n (% of total HSCT)
Matched related (sibling donor) 23 (49 %)
Unrelated (10/10 or 9/10 HLA
matched)
18 (38 %)
10/10 9
9/10 9
Total-body irradiation 15 (32 %)
Acute GVHD incidence, n (%)
Acute grades 0-II 35 (74%)
Acute grades III-IV 12 (26%)
GVHD indicates graft-versus-host disease; HSCT, hematopoietic stem
cell transplantation.
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first line of treatment.
Forty-four out of 47 patients had no AdV in the
blood and no clinical signs of AdV infection.
Three out of 47 patients had positive AdV-
DNAemia, and 3 out of 3 developed severe AdV-
associated disease. The 3 children (14, 9, and 4 years
of age) presented with acute lymphoid leukemia. Two
received 1 allogeneic 9/10 HLA-matched unrelated
HSCT after TBI-based myeloablative conditioning
regimen. The third received a second allogeneic
HSCT from another 9/10 HLA-matched unrelated
donor after a nonmyeloablative conditioning regimen
because of primary graft rejection. In 2 patients, AdV
was detected in the blood during weekly surveillance
within the first 3 months post-HSCT (day 74 and 75
post-HSCT, respectively). In the third patient, the
virus was detected later, in month 5 post-HSCT,
whereas AdV-PCR was maintained because of inten-
sive immunosuppression to treat cGVHD. DNAemia
still remained positive in the 3 patients despite
cidofovir treatment. Two who developed severe
AdV-associated gut disease recovered following anti-
AdV CTL infusion (prepared by or according to
Feuchtinger’s group as previously described) [34]. The
third died before CTL infusion. At the time of AdV-
DNAemia appearance, the distribution of lymphocyte
subpopulations in these patientswas 71 and28 lympho-
cytes/mL in cases 1 and 2 but 851 lymphocytes/mL in
the third (1, 3, and 337 CD31 T-lymphocytes/mL,
respectively).Enumeration of AdV-Specific IFN-g
and/or IL2-Secreting Cells
AdV-specific IFN-g and/or IL2-secreting cells
were enumerated by flow-cytometry after intracellular
IFN-g and/or IL2 staining as previously described
[25]. In brief, 106/mL peripheral blood mononuclear
cells (PBMCs) were resuspended in RPMI 1640 sup-
plemented with 10% heat-inactivated fetal calf serum,
10 IU/mL of recombinant IL-2, 2 mg/mL of CD28 an-
tibody (Beckman Coulter Company, Marseille, France),
and 2 mg/mL of CD49d antibody with brefeldin A (10
mg/mL) being added after 1 hour. Unstimulated cells
were used as negative control and cells stimulated by
0.2 mg/mL of CD3 antibodies were used as positive con-
trol. The Virion antigenic preparation (Virion, Zurich
Switzerland) commercialized consensus preparation of
inactivated AdV lysate including serotypes 3, 4, 6,
and 7 was used for specific stimulation. Based on the
well-known reactivity of T cells to epitope shared by
most serotypes, this preparation is supposed to detect
cellular immunity to virtually all epitopes [39]. The
specificity of this preparation was determined in prelim-
inary experiments showing a strict correlation between
reactivity to AdV peptides (peptivator-AdV hexon from
Miltenic Biotec, Bergisch Glabach, Germany) and the
viral lysate but no reactivity to CMV lysate (Abcys,
Paris, France) in CMV-seronegative individuals.
Cultures were incubated at 37C in a humidified 5%
CO2 atmosphere for 18 hours. After fixation and perme-
abilization, cells were labeled with CD3-FITC, CD4-
PECy5, and IFN-g-PE (BD Biosciences, Le Pont de
Claix, France) or CD3-FITC (Beckman Coulter,
Marseille, France), CD4-PerCP, IFN-g-PE, IL2-
APC (BD Biosciences).
Analysis was performed on a FACSCalibur instru-
ment using CellQuestPro software. A minimum of
100,000eventswasacquiredaftergatingonsmall lympho-
cytes, CD31, andCD41 cells. The percentage of specific
cells secreting cytokines was the percentage after AdV
stimulation minus the percentage of unstimulated cells.
IFN-g responses over 0.03% were considered pos-
itive provided that $2 times over the background.
Background consisted in culture including CD28 and
CD49d antibodies but no AdV antigen. This method
is based on a previous study comparing CMV-
specific IFN-g responses between CMV seropositive
and seronegative individuals [25].
Of note, the median of IFN-g responses in unsti-
mulated culture (containing anti-CD49d and -CD28
antibodies but no AdV antigen) in this study were
0.06% (range: 0.01-0.19) at month 1 post-HSCT and
0.05% (range: 0.01-0.28) at month 3 post-HSCT
versus 0.13% (range: 0.01-1.52) and 0.20% (range:
0.01-7.98) at month 1 and month 3, respectively, in
AdV-stimulated culture such as the noise of the back-
ground was well below true AdV-specific response.
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PBMCs were seeded (105 cells/well in triplicate) in
RPMI 1640 medium supplemented with 10% heat-
inactived pooled human sera, 1% L-glutamine, peni-
cillin, streptomycin (Sigma, Saint-Quentin-Fallavier,
France). Cells were either stimulated with the AdV
antigen (Virion), at a dilution of 0.1% for 6 days, or un-
stimulated (negative controls). Positive control con-
sisted of cells stimulated by coated CD3 antibodies
with CD28 antibodies at 0.6 mg/mL. [3H]-thymidine
(3HT) was added for the last 18 hours of culture.
Results are given in counts per minute (cpm) and
stimulation index (SI). An SI .5 associated with
cpm .5000 was considered to be a positive response.RESULTS
Adenovirus-Specific T Cell Responses in
Healthy Controls
At first, we addressed the effect of young age on the
level intensities of AdV-specific responses by compar-
ing responses in healthy adults (blood volunteer
donors) and children (family HSCT donors). An
AdV lysate that activates mostly the CD4 compart-
ment was used to stimulate blood lymphocytes.
According to epidemiologic background in our
region, all healthy adults appeared immunized as
evidenced by positive proliferative responses to AdV.
Yet, IFN-g secretionwasnotobserved in2of them, sug-
gesting a lower sensitivity of IFN-g than proliferative
assays to detect immune adults. CD41 T cells but not
CD81Tcells led to secretion above0.03% (not shown).
More than 10-fold variations in the frequencies of AdV-
specificCD41Tcells between individuals was observed
(median of positive values: 0.13%; range: 0.04-0.69).
Thirty out of 34 (88%) healthy children (median
age: 5.39 years; range: 0.46-14.91) evidenced AdV-
specific cellular immunity. In brief, 23 evidenced
both IFN-g and proliferative responses, 7 evidenced
proliferative (n5 4) or IFN-g (n5 3) responses alone,
and 4 did not evidence any response.
In children, as in adults, IFN-g–secreting cells
were mostly CD41 T cells with median frequencies
(0.12%, range: 0.04 to 0.39%) similar to those found
in adults. In children, enumeration of CD4 T cells/
mL of blood was simultaneously performed to provide
the results as percentages and also as absolute counts.
The median of AdV-specific CD4 secreting IFN-g
was 1.35/mL.Recovery of AdV-Specific IFN-g Responses
Related to AdV-DNAemia in HSCT
HSCT recipient cells that secreted IFN-g in
response to AdV lysate were also identified as CD41T cells (not shown). Individual data from the 47
HSCT recipients are reported separately according
to the nature of the graft in Figure 1. Note that the
technical failure rate was low at month 3 (M3)
(\10%) in both related and unrelated BMT and also
in cord blood HSCT. A higher rate, however, was
observed at month 1 (M1), especially in unrelated
BMT and cord blood HSCT because of major T cell
lymphopenia at that early time.
Three out of 47 HSCT recipients developed AdV-
DNAemia followed by severe AdV-associated disease
as detailed in Materials and Methods. All 3 had been
transplanted with 9/10 HLA-matched unrelated
HSCT. IFN-g responses to AdV were not detected
in T cells following in vitro stimulation with AdV
lysate at M3 in these 3 recipients.
Forty-four out of 47 patients did not evidence AdV
in the blood and/or clinical symptoms of AdV infection.
IFN-g responses to the virus were observed in 32 out of
those 44 (73%): since the first month post-HSCT (M1)
in 11 out of 19 evaluable at that time and since the
third month (M3) in 21 additional patients.
Data analysis reveals 5 main features. First, early
appearance since M1 of AdV-specific CD4 was
observed in both related and unrelated HSCT but
not in this limited series of cord HSCT. Second, the
incidence of AdV-specific immune recovery was high
at M3 in genoidentical BMT (70%) unrelated BMT
(80%) or cord blood HSCT (67%) and approached
the incidence of AdV-specific CD4 immunity in age-
matched healthy children (88%). Third, level intensi-
ties at M3 were highly similar in related and unrelated
BMT (0.19% for both; 0.36 and 0.21 CD4/mL, respec-
tively), although higher in the limited series of cord
blood HSCT (2.06%; 1.49 CD4/mL). Fourth, the per-
centages of AdV-specific CD41T cells were higher, at
M3, in transplanted children (over all median of posi-
tive values: 0.26%) as in healthy children (median of
positive values: 0.12%). In contrast, absolute counts
were lower in transplanted children (Figure 1) than
was observed in healthy children (median: 1.35/mL).
This observation indicates that T cell reconstitution
of AdV-specific CD4 T cells was relatively more
pronounced in magnitude than total CD41 during
immune recovery inHSCT. Finally, it is worth noting,
as shown in Figure 2, that all 3 recipients who devel-
oped no IFN-g response to AdV but did develop
AdV-DNAemia were found in 9/10 HLA-matched
unrelated HSCT in this limited series of patients.Recovery of AdV-Specific Proliferative
Responses following HSCT
Individual data on the proliferative responses to the
viral antigen are shown in Figure 3. Proliferative re-
sponses developed in all recipients with AdV-specific
Figure 1. Early development of IFN-g response to AdV is shown in a high proportion of pediatric patients with undetectable AdV-DNAemia but not in
3 out of 3 with severe AdV-associated disease. An intracytoplasmic cytokine assay was used to enumerate IFN-g-secreting bloodCD4T cells following in
vitro stimulation with AdV lysate. The percentages of CD4 T cells secreting IFN-g in stimulated cultures minus the percentages of CD4 T cells secreting
IFN-g in unstimulated cultures are given as individual values in genoidentical (n5 23), unrelated$9/10 HLA-matched (n5 18), and cord blood (n5 6)
HSCTrecipients. Absolute counts are the percentages multiplied by the absolute counts of blood CD4. The number of individuals (n) evaluable at month
1 (M1) and month 3 (M3) post-HSCT is indicated in parenthesis. Dashed bars indicate the threshold of positivity, that is, 0.03%. Horizontal (–) bars
indicates the median only in responders (only the responses over 0.03% were taken into account).
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sity levels of proliferation related to IFN-g responses
clearly depended on the time of sampling. At M1
post-HSCT, 1 out of the 12 patients who exhibited
IFN-g responses also exhibited proliferative responses
whereas 14 out of 23 (61%) did it at M3, 10 out of 12
(83%) at M6, and all at M12. This observation indi-
cates that AdV-specific immunity consisted first of
the development of an IFN-g response followed by
a second phase during which cells acquire the capacity
to proliferate.Distribution of Cytokine Responses Related to
Proliferative Responses
Simultaneous quantification of AdV-specific IL2
and IFN-g–secreting CD41 T cells on the one hand
and of proliferative responses on the other hand was
performed at least on 1 occasion in 39 transplanted
patients and also in 9 healthy adults and 8 healthy chil-
dren (mean age: 5.7 years). As shown in Figure 5, 3
populations of CD41 T cells were identified (single
IL2-secreting cells, single IFN-g–secreting cells and
IL2/IFN-g–secreting cells). In healthy adults and
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Figure 2. Distribution of AdV-specific cellular immunity and AdV-DNAemia related to the type of transplant. AdV responders were defined as individuals
with$0.03%AdV-specificCD4T cells secreting IFN-g (see legend to Figure 1). AdV in bloodwas evaluated byAdV PCR.Results are given as percentages of
patients fromgenoidentical (n5 23), 10/10HLA-matched unrelated (n5 9), 9/10HLA-matched unrelatedHSCT (n5 9), and cord blood (n5 6)HSCTwho
had AdV-specific CD4 above the threshold of positivity but undetectable AdV-DNAemia (open column) or AdV-specific CD4 under the threshold of
positivity and AdV-DNAemia (shaded column), or AdV-specific CD4 under the threshold of positivity without AdV-DNAemia (striped column).
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(median: 0.09% in both), followed by IFN-g, whereas
fewer cells secreted only IL2. In contrast, a higher
proportion of CD41 T cells secreting IFN-g alone
was observed at M1-M3 post-HSCT. A conversion
to predominant polyfunctional CD41 T cells, how-
ever, was observed atM6-M12. Finally, the proportion
of CD41T cells secreting IL2 alone was not decreased
and even increased in HSCT recipients at any time
post-transplant.DISCUSSION
In this article, we show that, under our experimen-
tal conditions, CD41 T cells dominated cytokine re-
sponses to AdV in both healthy adults and children
and also in HSCT recipients. These data agree with
those from the group of Feuchtinger that also used
an inactivated lysated virus as a source of antigen
known to preferentially activate CD4 T cells [17].
In an attempt to also explore CD8T cell responses,
AdV peptides (Peptivator-AdV hexon from Milteny
Biotec) were also assessed in the early times of the
study. In our hands, they also preferentially activated
CD4 T cells, although to lower levels than AdV lysate
(not shown). One interpretation of this observation is
that according to their characteristics (15 residue
length), they should also bind preferentially to HLA
class II molecules. Whether CD4 or CD8 could be
a better predictor of infectious risk was therefore not
addressed in the present study.
IFN-g responses to AdV developed in 61% of
patients in our series (in 73% with undetectable AdV
in the blood). Reminiscent of this observation, Feuch-
tinger et al. [34] previously reported that AdV-specificT cells could be detected although at lower frequency
in 53.5% of children without AdV-DNAemia follow-
ing HSCT. As adenovirus is known to persist in
epithelial cells and lymphoid tissue, at least in children
[40-42], the most likely explanation for this finding is
that AdV immune recovery was driven by AdV
replication present in other body sites. In line with
this interpretation, the presence of AdV in stool or
throat specimens is a very common finding in
pediatric HSCT, and in most instances, the virus is
spontaneously cleared by the recipients in the
absence of any clinical sign of infection [8].
Recovery of AdV-specific CD4 was rapid, occur-
ring within the first month post-HSCT in both related
(7 out of 13 evaluable) and unrelated (3 out of 5 evalu-
able) HSCT recipients. These data contrast with the
Myers et al. study showing the ability of related
HSCT recipients to mount an AdV-specific T cell
response after the first month, but there was delayed
recovery to at least 3 months in unrelated HSCT re-
cipients. T cell depletion by alemtuzumab is known
to delay immune recovery and was used in the Myers
et al. study, which provides a possible explanation of
why in vivo or ex vivo T cell depletion occurred in
a lower proportion of unrelated HSCT in our series.
It is worth noting that in cord HSCT, including in
all cases antithymocyte globulin, 0 out of 3 recipients
that were evaluable at M1 reconstituted AdV
immunity, whereas 3 out of 5 did at month 3. Further
studies with larger sample sizes could determine the
influence of various parameters as the conditioning
regimen or the nature of the graft in the kinetics of
AdV-specific immune recovery.
Several studies have suggested an association be-
tween the presence of AdV-specific IFN-g responses
and virus control [18,34,35]. None of the 33 patients
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CD4/mL of blood evidenced ADV-DNAemia. On
the contrary, AdV-specific CD4 was under the
threshold of detection in 3 out of 3 patients with
ADV-DNAemia. Furthermore, resistance to anti-
AdV chemotherapy was observed in the 3 patients.
AdV-DNAemia in the absence of immunologic recon-
stitution would therefore induce physicians to indicate
preparation and administration of anti-AdV–specific
T cells.
It is worth noting that 0 out of 10 (0%) nonre-
sponders who received a genoidentical or 10/10
HLA-matched or cord blood HSCT developedAdV-DNAemia. In contrast, 3 out of 4 (75%)
nonresponders among 9/10 HLA-matched unrelated
BMT evidenced AdV dissemination. Although the
small size of the sample precludes firm conclusions
from being drawn, these data suggest that partly
HLA-matched unrelated BMT with undetectable
AdV-specific CD4 at M3 defines a population at risk
of severe AdV infection.
Recently, Lion et al. found a relation between AdV
levels over 106 copies per mg in stool specimens and
subsequent blood dissemination. The authors pro-
posed that this threshold would serve as a basis for
initiation of preemptive antiviral treatment. It could
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pearance of proliferative responses IFN-g responses toAdV (see the leg-
end in Figure 1) were plotted against proliferative responses to AdV (see
the legend in Figure 3) fromeach individual evaluable for both functions at
the same time.Dashed bars indicate the threshold of positivity (0.03% for
IFN-g responses and 5000 cpm with an SI $5 for proliferative re-
sponses). Medians of IFN-g responses over 0.03% were 0.19% at month
1 (M1), 0.26% at month 3 (M3), 0.16% at month 6 (M6), and 0.14% at
month 12 (M12). Median of proliferative responses over 5000 cpm
were 34,871 cpm at M3, 33,255 cpm at M6, and 50,536 cpm at M12.
Biol Blood Marrow Transplant 17:476-485, 2011 483Adenovirus Cellular Immunity in Transplanted Childrenbe interesting to determine whether monitoring both
adenovirus load in stool and immunity to AdV could
improve early identification of patients unable tocontain the virus even under anti-AdV chemotherapy.
If so, specific anti-AdV T cell preparations could be
planned in advance in addition to antiviral chemother-
apy for optimal efficiency. Quantification of AdV-
PCR in stool and other body sites could also help in
the discrimination between high-risk nonresponders
because of unresponsiveness and low-risk nonre-
sponders because of unexposure to the virus.
Distinct functional phenotypes of memory T cells
have been described. Effector memory cells possess im-
mediate effector functions, among which is IFN-g
secretion, but reduced ability to proliferate and secrete
IL2. They are thought to be primarily involved in viral
clearance. Central memory cells that proliferate and
secrete high levels of IL2, however, appear required
for full protection in various infectious models
[28-33]. To our knowledge, this is the first report that
describes immune recovery to AdV according to the
recent advance in the complexity of memory T cell
development. Our data show earlier acquisition of
IFN-g responses related to proliferative responses
and a trend toward higher IFN-g than polyfunctional
responses at early times post-HSCT. This observation
supports that effector-memory CD41 T cells (ie,
CD41 T cells secreting IFN-g alone) expanded first,
followed by the expansion of, or conversion into, cen-
tral memory cells with high in vitro proliferative capac-
ity. In line with this observation, gradual acquisition of
IFN-g response followed by delayed appearance of
lymphoproliferative or IL2 responses has been reported
in CMV infection [23-25,43]. In clinical practice, IFN-
g responses that develop first in the host appear to be
the most pertinent marker for risk evaluation at early
post-HSCT. The functional significance of these dif-
ferent functional phenotypes, however, remains to be
fully determined with regard to protective efficacy.
These studies could indeed improve our ability to
design AdV-specific cellular therapy.
Finally, the kinetics of cellular immune recovery
toward ADV acute infection (this article) and toward
CMV persistent infection [25] were not dramatically
different. One possible explanation is that immune re-
covery is driven by viruses present in the recipient at
the time of transplant in both infections. In line with
this hypothesis, de Pagter et al. [44] recently reported
AdV-DNA positivity in nasopharyngeal aspirate in
a high proportion of patients before HSCT. Virologic
investigations at the time of HSCT would therefore
also help in delineating at risk children.ACKNOWLEDGMENTS
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Figure 5. IFN-g responses to AdV preceeded the appearance of AdV-specific polyfunctional (IL21 IFN-g secreting) CD4 T cells following HSCT. An
intracytoplasmic assay was used to enumerate CD4 T cells that secrete IFN-g alone, IL2 alone, or both cytokines following AdV-stimulation (see legend
to Figure 1). On the left, data from 1 representative healthy adult (A), healthy child (B), and 1 representative pediatric HSCT: at months 1-3 (M1-M3) (C)
and at months 6-12 (M6-M12) post-HSCT (D) are shown as dot-plot. Dot-plots were obtained after lymphocyte gating and subsequent CD31 and
CD41 cell gating. In the middle, results are also shown as individual % of CD41 T cells secreting IL2 alone, IFN-g alone or both IL2/IFN-g in healthy
adults (top), children (middle high), or HSCT recipients at months 1-3 (M1-M3) post-HSCT (middle low), or months 6-12 (M6-M12) post-HSCT
(bottom). On the right, the median of % of CD41 T cells secreting cytokines are illustrated: IL2 (solid); IFN-g (shaded); IFN-g and IL2 (striped).
484 Biol Blood Marrow Transplant 17:476-485, 2011V. Guerin-El Khourouj et al.Finally, we greatly thank Celine Neto for preparing
the manuscript.
The authors report no conflicts of interest.
Financial disclosure:This work was partly supported
by Assistance Publique-Ho^pitaux de Paris.AUTHORSHIP STATEMENT
Valerie Guerin-El Khourouj performed the re-
search, analyzed the data in HSCT patients, and wrote
the manuscript. Jean-Hugues Dalle took care of pa-
tients, analyzed the data, and wrote the manuscript.
Beatrice Pedron analyzed the data in HSCT patients.
Marie Ouachee-Chardin and Karima Yakouben took
care of patients and analyzed the data. Daniele
Bensoussan contributed to analyzing the data and care-
fully reading the manuscript. Debora Jorge Cordeiro
and Lucas Peltier contributed to the study of healthy
children and healthy adults, and contributed to writingthe manuscript. Andre Baruchel designed the study
and analyzed the data. Ghislaine Sterkers designed
the study, contributed to analyzing the data and wrote
the manuscript.REFERENCES
1. Wigger HJ, Blanc WA. Fatal hepatic and bronchial necrosis in
adenovirus infection with thymic alymphoplasia. N Engl
J Med. 1966;275:870-874.
2. Wensley DF, Baldwin VJ. Respiratory distress in the second
week of life. J Pediatr. 1985;106:326-331.
3. Abzug MJ, Levin MJ. Neonatal adenovirus infection: four
patients and review of the literature. Pediatrics. 1991;87:890-896.
4. Kojaoghlanian T, Flomenberg P, Horwitz MS. The impact of
adenovirus infection on the immunocompromised host. Rev
Med Virol. 2003;13:155-171.
5. Echavarria M, FormanM, van Tol MJ, Vossen JM, Charache P,
Kroes AC. Prediction of severe disseminated adenovirus
infection by serum PCR. Lancet. 2001;358:384-385.
6. van TolMJ, Claas EC,Heemskerk B, et al. Adenovirus infection
in children after allogeneic stem cell transplantation: diagnosis,
Biol Blood Marrow Transplant 17:476-485, 2011 485Adenovirus Cellular Immunity in Transplanted Childrentreatment and immunity. Bone Marrow Transplant. 2005;35
(Suppl 1):S73-S76.
7. Feuchtinger T, Lang P, Handgretinger R. Adenovirus infection
after allogeneic stem cell transplantation. Leuk Lymphoma. 2007;
48:244-255.
8. Lion T, Baumgartinger R, Watzinger F, et al. Molecular moni-
toring of adenovirus in peripheral blood after allogeneic bone
marrow transplantation permits early diagnosis of disseminated
disease. Blood. 2003;102:1114-1120.
9. Myers GD, Krance RA, Weiss H, et al. Adenovirus infection
rates in pediatric recipients of alternate donor allogeneic bone
marrow transplants receiving either antithymocyte globulin
(ATG) or alemtuzumab (Campath). Bone Marrow Transplant.
2005;36:1001-1008.
10. Schilham MW, Claas EC, van Zaane W, et al. High levels of
adenovirus DNA in serum correlate with fatal outcome of
adenovirus infection in children after allogeneic stem-cell trans-
plantation. Clin Infect Dis. 2002;35:526-532.
11. Lenaerts L, Naesens L. Antiviral therapy for adenovirus infec-
tions. Antiviral Res. 2006;71:172-180.
12. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus
infections following allogeneic stem cell transplantation: inci-
dence and outcome in relation to graft manipulation, immuno-
suppression, and immune recovery. Blood. 2002;100:1619-1627.
13. Kampmann B, Cubitt D, Walls T, et al. Improved outcome for
children with disseminated adenoviral infection following alloge-
neic stem cell transplantation. Br J Haematol. 2005;130:595-603.
14. Avivi I, Chakrabarti S, Milligan DW, et al. Incidence and
outcome of adenovirus disease in transplant recipients after
reduced-intensity conditioning with alemtuzumab. Biol Blood
Marrow Transplant. 2004;10:186-194.
15. Leen AM, Bollard CM, Myers GD, Rooney CM. Adenoviral
infections in hematopoietic stem cell transplantation. Biol Blood
Marrow Transplant. 2006;12:243-251.
16. Heemskerk B, Lankester AC, van Vreeswijk T, et al. Immune
reconstitution and clearance of human adenovirus viremia in
pediatric stem-cell recipients. J Infect Dis. 2005;191:520-530.
17. Feuchtinger T, Lucke J, Hamprecht K, et al. Detection of
adenovirus-specific T cells in children with adenovirus infection
after allogeneic stem cell transplantation. Br J Haematol. 2005;
128:503-509.
18. Myers GD, Bollard CM, Wu MF, et al. Reconstitution of
adenovirus-specific cell-mediated immunity in pediatric patients
after hematopoietic stem cell transplantation. Bone Marrow
Transplant. 2007;39:677-686.
19. Schoenberger SP, Toes RE, van der Voort EI, Offringa R,
Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated
by CD40-CD40L interactions. Nature. 1998;393:480-483.
20. Shedlock DJ, Shen H. Requirement for CD4 T cell help in
generating functional CD8 T cell memory. Science. 2003;300:
337-339.
21. Sun JC, BevanMJ.Defective CD8T cell memory following acute
infection without CD4 T cell help. Science. 2003;300:339-342.
22. Klenerman P, Hill A. T cells and viral persistence: lessons from
diverse infections. Nat Immunol. 2005;6:873-879.
23. Lilleri D, Fornara C, Furione M, Zavattoni M, Revello MG,
Gerna G. Development of human cytomegalovirus-specific T
cell immunity during primary infection of pregnant women
and its correlation with virus transmission to the fetus. J Infect
Dis. 2007;195:1062-1070.
24. Lilleri D, Fornara C, Revello MG, Gerna G. Human
cytomegalovirus-specificmemoryCD81 andCD41Tcell differ-
entiation after primary infection. J Infect Dis. 2008;198:536-543.
25. Guerin V, Dalle JH, Pedron B, et al. Cellular immune parame-
ters associated with spontaneous control of CMV in children
who underwent transplantation. Bone Marrow Transplant. 2010;
45:442-449.
26. Pourgheysari B, Piper KP, McLarnon A, et al. Early reconstitu-
tion of effector memory CD41 CMV-specific T cells protectsagainst CMV reactivation following allogeneic SCT. Bone Mar-
row Transplant. 2009;43:853-861.
27. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of
cellular immunity against cytomegalovirus in recipients of allo-
geneic bonemarrow by transfer of T-cell clones from the donor.
N Engl J Med. 1995;333:1038-1044.
28. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A.
Presence of HIV-1 Gag-specific IFN-gamma1IL-21 and
CD281IL-21 CD4 T cell responses is associated with nonprog-
ression in HIV-1 infection. J Immunol. 2002;169:6376-6385.
29. Darrah PA, Patel DT, De Luca PM, et al. Multifunctional TH1
cells define a correlate of vaccine-mediated protection against
Leishmania major. Nat Med. 2007;13:843-850.
30. Emu B, Sinclair E, Favre D, et al. Phenotypic, functional, and
kinetic parameters associated with apparent T-cell control of
human immunodeficiency virus replication in individuals with and
without antiretroviral treatment. J Virol. 2005;79:14169-14178.
31. Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional
heterogeneity of memory CD4 T cell responses in different
conditions of antigen exposure and persistence. J Immunol.
2005;174:1037-1045.
32. Millington KA, Innes JA, Hackforth S, et al. Dynamic relation-
ship between IFN-gamma and IL-2 profile of Mycobacterium
tuberculosis-specific T cells and antigen load. J Immunol. 2007;
178:5217-5226.
33. Younes SA, Yassine-Diab B, Dumont AR, et al. HIV-1 viremia
prevents the establishment of interleukin 2-producing HIV-
specific memory CD41 T cells endowed with proliferative
capacity. J Exp Med. 2003;198:1909-1922.
34. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adop-
tive transfer of virus-specific T-cell immunity for the treatment
of systemic adenovirus infection after allogeneic stem cell
transplantation. Br J Haematol. 2006;134:64-76.
35. Leen AM, Myers GD, Sili U, et al. Monoculture-derived
T lymphocytes specific for multiple viruses expand and produce
clinically relevant effects in immunocompromised individuals.
Nat Med. 2006;12:1160-1166.
36. Flomenberg P, Piaskowski V, Truitt RL, Casper JT. Character-
ization of human proliferative T cell responses to adenovirus.
J Infect Dis. 1995;171:1090-1096.
37. Souberbielle BE, Russell WC. Human T cell proliferative
response to polypeptides from adenovirus type 2. J Infect Dis.
1995;172:1421-1422.
38. Heim A, Ebnet C, Harste G, Pring-Akerblom P. Rapid and
quantitative detection of human adenovirus DNA by real-time
PCR. J Med Virol. 2003;70:228-239.
39. Veltrop-Duits LA, Heemskerk B, Sombroek CC, et al. Human
CD41 T cells stimulated by conserved adenovirus 5 hexon
peptides recognize cells infected with different species of human
adenovirus. Eur J Immunol. 2006;36:2410-2423.
40. Garnett CT, Erdman D, Xu W, Gooding LR. Prevalence and
quantitation of species C adenovirus DNA in human mucosal
lymphocytes. J Virol. 2002;76:10608-10616.
41. Leung AY, Chan M, Cheng VC, Yuen KY, Kwong YL. Quanti-
fication of adenovirus in the lower respiratory tract of patients
without clinical adenovirus-related respiratory disease. Clin
Infect Dis. 2005;40:1541-1544.
42. Neumann R, Genersch E, Eggers HJ. Detection of adenovirus
nucleic acid sequences in human tonsils in the absence of infec-
tious virus. Virus Res. 1987;7:93-97.
43. Revello MG, Lilleri D, Zavattoni M, et al. Lymphoproliferative
response in primary human cytomegalovirus (HCMV) infection
is delayed in HCMV transmitter mothers. J Infect Dis. 2006;193:
269-276.
44. de Pagter AP, Haveman LM, Schuurman R, Schutten M,
Bierings M, Boelens JJ. Adenovirus DNA positivity in nasopha-
ryngeal aspirate preceding hematopoietic stem cell transplanta-
tion: a very strong risk factor for adenovirus DNAemia in
pediatric patients. Clin Infect Dis. 2009;49:1536-1539.
